Search CTL/CD8+ T-Cell Epitope Database

Found 7 matching records:

Displaying record number 53812

Download this epitope record as JSON.

HXB2 Location	gp160(37-45) gp120(37-45) DNA(6333..6359)	gp160 Epitope Map
Author Location	gp160
Epitope	`TVYYGVPVW`	Epitope Alignment
Subtype	A, B, C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	A29:02, A29:02, B15:03, B18:01, C02:02, C12:03; A30:01, A66:01, B57:03, B58:01, C04:01, C18:01
Country	Kenya
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	A clade, B clade, D clade NDK, C clade consensus
Vaccine component	Env

Notes

Interclade cross-reactivity of clades A, B, C, and D was tested using recombinant vaccinia-based IFN-gamma Elispot assay. 47/74 women had a positive Elispot response to at least one clade, and cross-clade responses were frequent. Clade A responses were most frequent, as expected, as clade A dominates the Kenyan epidemic (85% of the 47 women responded to clade A Env, 74% to B, 62% to C, and 43% to D). Cross-clade CD8 T-cell responses were common and directed at conserved epitopes.
There was a greater magnitude of response to A clade peptides in individuals who responded to more than 1 clade; a 2-fold higher response was observed in clade A in 36% (9/25) of these individuals, and the response to A peptides was never lower. TVYYGVPVW responses were detected in 2 women who reacted to all clades tested, A, B, C, and D, and the sequence was identical in all clades.

References

McKinnon2005 Lyle R. McKinnon, T. Blake Ball, Joshua Kimani, Charles Wachihi, Lucy Matu, Ma Luo, Joanne Embree, Keith R. Fowke, and Francis A. Plummer. Cross-Clade CD8+ T-Cell Responses With a Preference for the Predominant Circulating Clade. J. Acquir. Immune Defic. Syndr., 40(3):245-249, 1 Nov 2005. PubMed ID: 16249696. Show all entries for this paper.

Displaying record number 53806

Download this epitope record as JSON.

HXB2 Location	gp160(89-97) gp120(89-97) DNA(6489..6515)	gp160 Epitope Map
Author Location	gp160
Epitope	`VTEEFNMWK`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	A32:01, A36:01, B53:01, B81:01, C04:01, C08:04; A24:02, A32:01, B51:01, B53:01, C04:01, C06:02
Country	Kenya
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	A clade, B clade, D clade NDK, C clade consensus
Vaccine component	Env

Notes

Interclade cross-reactivity of clades A, B, C, and D was tested using recombinant vaccinia-based IFN-gamma Elispot assay. 47/74 women had a positive Elispot response to at least one clade, and cross-clade responses were frequent. Clade A responses were most frequent, as expected, as clade A dominates the Kenyan epidemic (85% of the 47 women responded to clade A Env, 74% to B, 62% to C, and 43% to D). Cross-clade CD8 T-cell responses were common and directed at conserved epitopes.
There was a greater magnitude of response to A clade peptides in individuals who responded to more than 1 clade; a 2-fold higher response was observed in clade A in 36% (9/25) of these individuals, and the response to A peptides was never lower. VTEEFNMWK responses were detected in 2 women who had Env responses to all 4 clades, and clade A gave the highest responses; a VnEEFNMWK variant was in clade B and D, and the clade C Env carried VnEEFNMWe. One woman also reacted with RAIEAQQHL, the other with KNCSFNMTT.
Both women that reacted with VTEEFNMWK carried HLA-B*5301, the only common HLA allele.

References

Displaying record number 53810

Download this epitope record as JSON.

HXB2 Location	gp160(155-163) gp120(155-163) DNA(6687..6713)	gp160 Epitope Map
Author Location	gp160
Epitope	`KNCSFNMTT`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	A24:02, A32:01, B51:01, B53:01, C04:01, C16:04
Country	Kenya
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	A clade, B clade, D clade NDK, C clade consensus
Vaccine component	Env

Notes

Interclade cross-reactivity of clades A, B, C, and D was tested using recombinant vaccinia-based IFN-gamma Elispot assay. 47/74 women had a positive Elispot response to at least one clade, and cross-clade responses were frequent. Clade A responses were most frequent, as expected, as clade A dominates the Kenyan epidemic (85% of the 47 women responded to clade A Env, 74% to B, 62% to C, and 43% to D). Cross-clade CD8 T-cell responses were common and directed at conserved epitopes.
There was a greater magnitude of response to A clade peptides in individuals who responded to more than 1 clade; a 2-fold higher response was observed in clade A in 36% (9/25) of these individuals, and the response to A peptides was never lower. VTEEFNMWK responses were detected in 2 women who had Env responses to all 4 clades, and clade A gave the highest responses; a VnEEFNMWK variant was in clade B and D, and the clade C Env carried VnEEFNMWe. One woman also reacted with RAIEAQQHL, the other one with KNCSFNMTT. KNCSFNMTT was identical in clades A and C, while clade B carried KNCSFNMis, clade D carried KNiSFNMTT.

References

Displaying record number 53807

Download this epitope record as JSON.

HXB2 Location	gp160(557-565) gp41(46-54) DNA(7893..7919)	gp160 Epitope Map
Author Location	gp160
Epitope	`RAIEAQQHL`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	A32:01, A36:01, B53:01, B81:01, C04:01, C08:04
Country	Kenya
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	A clade, B clade, D clade NDK, C clade consensus
Vaccine component	Env

Notes

Interclade cross-reactivity of clades A, B, C, and D was tested using recombinant vaccinia-based IFN-gamma Elispot assay. 47/74 women had a positive Elispot response to at least one clade, and cross-clade responses were frequent. Clade A responses were most frequent, as expected, as clade A dominates the Kenyan epidemic (85% of the 47 women responded to clade A Env, 74% to B, 62% to C, and 43% to D). Cross-clade CD8 T-cell responses were common and directed at conserved epitopes.
There was a greater magnitude of response to A clade peptides in individuals who responded to more than one clade; a 2-fold higher response was observed in clade A in 36% (9/25) of these individuals, and the response to A peptides was never lower. VTEEFNMWK responses were detected in 2 women that had Env responses to all 4 clades, and clade A gave the highest responses; a VnEEFNMWK variant was in clade B and D, and the clade C Env carried VnEEFNMWe. One woman also reacted with RAIEAQQHL, the other with KNCSFNMTT. RAIEAQQHL was identical in clades A, B, and D, while C carried RAIEAQQHm.

References

Displaying record number 53808

Download this epitope record as JSON.

HXB2 Location	gp160(584-592) gp41(73-81) DNA(7974..8000)	gp160 Epitope Map
Author Location	gp160
Epitope	`ERYLRDQQL`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	A02:02, A74:01, B15:03, B58:02, C02:02, C06:02; A02:01, A30:09, B45:01, B58:02, C02:02, C16:01
Country	Kenya
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	A clade, B clade, D clade NDK, C clade consensus
Vaccine component	Env

Notes

Interclade cross-reactivity of clades A, B, C, and D was tested using recombinant vaccinia-based IFN-gamma Elispot assay. 47/74 women had a positive Elispot response to at least one clade, and cross-clade responses were frequent. Clade A responses were most frequent, as expected, as clade A dominates the Kenyan epidemic (85% of the 47 women responded to clade A Env, 74% to B, 62% to C, and 43% to D). Cross-clade CD8 T-cell responses were common and directed at conserved epitopes.
There was a greater magnitude of response to A clade peptides in individuals who responded to more than 1 clade; a 2-fold higher response was observed in clade A in 36% (9/25) of these individuals, and the response to A peptides was never lower. ERYLRDQQL responses were detected in 2 women who had Env responses to all 4 clades, and clade A gave the highest responses; a ERYLkDQQL variant was in clade B and C, and the clade D Env carried ERsLkDQQL. The epitope VSGFLALAW was also recognized by 1 of the women.
HLA-B*5802 was the only HLA common to both women who reacted with ERYLRDQQL, so may be the presenting allele.

References

Displaying record number 53809

Download this epitope record as JSON.

HXB2 Location	gp160(749-757) gp41(238-246) DNA(8469..8495)	gp160 Epitope Map
Author Location	gp160
Epitope	`VSGFLALAW`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, vaccine
Patient MHC/HLA	A02:02, A74:01, B15:03, B58:02, C02:02, C06:02
Country	Kenya
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	A clade, B clade, D clade NDK, C clade consensus
Vaccine component	Env

Notes

Interclade cross-reactivity of clades A, B, C, and D was tested using recombinant vaccinia-based IFN-gamma Elispot assay. 47/74 women had a positive Elispot response to at least one clade, and cross-clade responses were frequent. Clade A responses were most frequent, as expected, as clade A dominates the Kenyan epidemic (85% of the 47 women responded to clade A Env, 74% to B, 62% to C, and 43% to D). Cross-clade CD8 T-cell responses were common and directed at conserved epitopes.
There was a greater magnitude of response to A clade peptides in individuals who responded to more than 1 clade; a 2-fold higher response was observed in clade A in 36% (9/25) of these individuals, and the response to A peptides was never lower. ERYLRDQQL responses were detected in 2 women who had Env responses to all 4 clades, and clade A gave the highest responses; an ERYLkDQQL variant was in clade B and C, and the clade D Env carried ERsLkDQQL. The epitope VSGFLALAW was also recognized by 1 of the women; A and C clade were identical, while clade B carried VnGsLiLAW, clade D VnGlsAiAW.

References

Displaying record number 53805

Download this epitope record as JSON.

HXB2 Location	gp160(843-851) gp41(332-340) DNA(8751..8777)	gp160 Epitope Map
Author Location	gp160( clade A, B, C, D)
Epitope	`IPRRIRQGL`	Epitope Alignment
		Show epitope variants
Subtype	A, B, C, D
Species (MHC/HLA)	human
Immunogen	HIV-1 infection
Patient MHC/HLA	A68:02, A68:02, B13:03, B14:01, C06:02, C17:01
Country	Kenya
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	subtype comparisons, variant cross-reactivity

Notes

Interclade cross-reactivity of clades A, B, C, and D was tested using recombinant vaccinia-based IFN-gamma Elispot assay. 47/74 women had a positive Elispot response to at least one clade, and cross-clade responses were frequent. Clade A responses were most frequent, as expected, as clade A dominates the Kenyan epidemic (85% of the 47 women responded to clade A Env, 74% to B, 62% to C, and 43% to D). Cross-clade CD8 T-cell responses were common and directed at conserved epitopes.
There was a greater magnitude of response to A clade peptides in individuals who responded to more than 1 clade; a 2-fold higher response was observed in clade A in 36% (9/25) of these individuals, and the response to A peptides was never lower. IPRRIRQGL responses were detected in all 4 clades in 1 woman: clade A gave a high response; IPRRIRQGL was identical clade B; clade C and D had lower responses and carried variant peptides IPRRIRQGf and IvRRIRQGL.